Use of Immune Checkpoint Inhibitors in Patients With Inflammatory Bowel Disease After Ileal Pouch-Anal Anastomosis-Reference-Cited by-同舟云学术

Use of Immune Checkpoint Inhibitors in Patients With Inflammatory Bowel Disease After Ileal Pouch-Anal Anastomosis

Published:2023-06-01 Issue: Volume: Page:
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Karime Christian¹^ORCID,Farraye Francis A²,Hashash Jana G²^ORCID

Affiliation:

1. Department of Internal Medicine, Mayo Clinic , Jacksonville, Florida , USA

2. Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, Florida , USA

Abstract

Lay Summary It is unknown if immune checkpoint inhibitor therapy increases risk of pouch-related complications in patients with inflammatory bowel disease after ileal-pouch anal anastomosis. In our study, pembrolizumab therapy was not associated with significant gastrointestinal immune-related adverse events or pouch-related complications.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

https://academic.oup.com/ibdjournal/advance-article-pdf/doi/10.1093/ibd/izad098/50501458/izad098.pdf

Reference8 articles.

1. Diagnosis and management of immune checkpoint inhibitor colitis;Hashash;Gastroenterol Hepatol (N Y),2021

2. Current diagnosis and management of immune related adverse events (irAEs) Induced by immune checkpoint inhibitor therapy;Kumar;Front Pharmacol.,2017

3. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease;Abu-Sbeih;J Clin Oncol.,2020

4. Ileal-anal pouches: a review of its history, indications, and complications;Ng;World J Gastroenterol.,2019

5. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients;Meagher;Br J Surg.,1998